Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $202.95, with a market capitalization of 30.26B. The stock trades at a price-to-earnings (P/E) ratio of 37.05.
On 2026-08-01, Biogen(BIIB) stock moved within a range of $202.57 to $208.05. With shares now at $202.95, the stock is trading +0.2% above its intraday low and -2.5% below the session's peak.
Trading activity shows a volume of 1.03M, compared to an average daily volume of 1.1M.
The stock's 52-week range extends from a low of $124.56 to a high of $219.72.
The stock's 52-week range extends from a low of $124.56 to a high of $219.72.
BIIB News
...
Biogen Inc. has reported its second-quarter 2026 results, with revenue rising to US$2.74 billion from US$2.65 billion a year earlier while net income dropped sh...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $231 from $222 and keeps an Equal Weight rating on the shares. Unlock p...
Analyst ratings
64%
of 36 ratingsMore BIIB News
H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $251 from $237 and keeps a Buy rating on the shares. The firm revisited its penetration assum...
Biogen Inc. ((BIIB)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Tip...
Key Points It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance. 10 stocks we...
Revenue Tops Expectations On Growth Across Key Products The Alzheimer’s drug maker reported revenues of $2.736 billion, beating the consensus of $2.458 billion...
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' 7/14/2026 Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowe...
Ami Fadia, an analyst from Needham, maintained the Buy rating on Biogen. The associated price target remains the same with $256.00. Unlock powerful investing t...
Advertisement Biogen earnings event and why it matters for shareholders Biogen (BIIB) has just reported second quarter 2026 earnings, giving investors fresh d...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.